Cargando…

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens

Personalized cancer care requires reliable biomarkers. While the BRAF V600E mutation is implemented in the clinic, no method for its detection has so far been established as reference. We aimed to perform a comprehensive comparison of three methods currently being used for V600E detection in clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Løes, Inger Marie, Immervoll, Heike, Angelsen, Jon-Helge, Horn, Arild, Geisler, Jürgen, Busch, Christian, Lønning, Per Eystein, Knappskog, Stian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342512/ https://www.ncbi.nlm.nih.gov/pubmed/25318602 http://dx.doi.org/10.1007/s13277-014-2711-5

Ejemplares similares

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
por: Løes, Inger Marie, et al.
Publicado: (2016)

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
por: Birkeland, Einar, et al.
Publicado: (2013)

Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection
por: Sveen, Anita, et al.
Publicado: (2016)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?
por: Lønning, Per Eystein, et al.
Publicado: (2018)

Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines
por: Huun, Johanna, et al.
Publicado: (2017)

ramr: an R/Bioconductor package for detection of rare aberrantly methylated regions
por: Nikolaienko, Oleksii, et al.
Publicado: (2021)

epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data
por: Nikolaienko, Oleksii, et al.
Publicado: (2023)

Constitutional Mosaic Epimutations - a hidden cause of cancer?
por: Lønning, Per E., et al.
Publicado: (2019)

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
por: Bjørnslett, Merete, et al.
Publicado: (2012)

Adjuvant treatment: the contribution of expression microarrays
por: Lønning, Per Eystein, et al.
Publicado: (2007)

Alterations of the retinoblastoma gene in metastatic breast cancer
por: Berge, Elisabet Ognedal, et al.
Publicado: (2011)

Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases
por: Angelsen, Jon-Helge, et al.
Publicado: (2015)

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2015)

The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
por: Poduval, Deepak, et al.
Publicado: (2020)

Correction: The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
por: Poduval, Deepak, et al.
Publicado: (2021)

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2013)

Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens
por: Frouin, Eric, et al.
Publicado: (2016)

DNA methylation subgroups in melanoma are associated with proliferative and immunological processes
por: Lauss, Martin, et al.
Publicado: (2015)

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk
por: Knappskog, Stian, et al.
Publicado: (2011)

Chemosensitivity and p53; new tricks by an old dog
por: Lønning, Per E, et al.
Publicado: (2012)

Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour
por: Straume, Anne Hege, et al.
Publicado: (2012)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival
por: Angelsen, Jon-Helge, et al.
Publicado: (2014)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

MDM4 SNP34091 (rs4245739) and its effect on breast‐, colon‐, lung‐, and prostate cancer risk
por: Gansmo, Liv B., et al.
Publicado: (2015)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers
por: Berge, Elisabet Ognedal, et al.
Publicado: (2010)

APOBEC3A/B deletion polymorphism and cancer risk
por: Gansmo, Liv B, et al.
Publicado: (2018)

High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function
por: Yndestad, Synnøve, et al.
Publicado: (2017)

Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma
por: Meckbach, Diana, et al.
Publicado: (2014)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

BRAF(V600E )mutations in malignant melanoma are associated with increased expressions of BAALC
por: Schrama, David, et al.
Publicado: (2008)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
por: Kocovski, Linda, et al.
Publicado: (2015)

BRAF V600 mutations and pathological features in Japanese melanoma patients
por: Yamazaki, Naoya, et al.
Publicado: (2015)

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot
por: Iwama, Eimei, et al.
Publicado: (2015)

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy
por: Eikesdal, Hans P., et al.
Publicado: (2014)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3drmqbaeuih8m7or9o6kj4tpvr